COMUNICADO: C8 MediSensors consigue la aprobación de la Marca CE para el sistema de monitorización óptico de glucosa de C8 MediSenso

[TAB] 1) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86 2) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131 ):837-53 3) Monnier L, Colette C, Boegner C, et al. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 2007;33(4):247-52 4) Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295(14):1681-7 5) Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008;10(5):377-83 6) Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract 2010;64(12):1705-11 7) Beck RW, Buckingham B, Miller K, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009;32(11):1947-53 8) Anderson J, Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice. J Diabetes Sci Technol 2011;5(6):1472-8 9) Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther 2007;9(3):203-10 10) Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26(4):1153-7 11) Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 2006;29(12):2644-9 12) Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.


[TAB]


1) The Diabetes Control and Complications Trial Research Group. The effect


of intensive treatment of diabetes on the development and progression of long-term


complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86


2) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control


with sulphonylureas or insulin compared with conventional treatment and risk of


complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131


):837-53


3) Monnier L, Colette C, Boegner C, et al. Continuous glucose monitoring in


patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 2007;33(4):247-52


4) Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute


glucose fluctuations compared with sustained chronic hyperglycemia in patients with


type 2 diabetes. JAMA 2006;295(14):1681-7


5) Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy:


results of the first randomized treat-to-target study. Diabetes Technol Ther


2008;10(5):377-83


6) Ceriello A. The glucose triad and its role in comprehensive glycaemic


control: current status, future management. Int J Clin Pract 2010;64(12):1705-11


7) Beck RW, Buckingham B, Miller K, et al. Factors predictive of use and of


benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care


2009;32(11):1947-53


8) Anderson J, Effect on glycemic control by short- and long-term use of


continuous glucose monitoring in clinical practice. J Diabetes Sci Technol


2011;5(6):1472-8


9) Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time


continuous glucose monitoring: results from a 12-week observational study. Diabetes


Technol Ther 2007;9(3):203-10


10) Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose


monitoring system is useful for detecting unrecognized hypoglycemias in patients with


type 1 and type 2 diabetes but is not better than frequent capillary glucose


measurements for improving metabolic control. Diabetes Care 2003;26(4):1153-7


11) Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels


to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using


a 7-day continuous glucose sensor. Diabetes Care 2006;29(12):2644-9


12) Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with


a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.


Diabetes Care 2006;29(1):44-50


13) Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous


glucose monitoring system: clinical decisions and glycemic control after its use in


pediatric type 1 diabetic subjects. Diabetes Care 2001;24(12):2030-4


14) Garg SK, Kelly WC, Voelmle MK, et al. Continuous home monitoring of glucose:


improved glycemic control with real life use of continuous glucose sensors in adult


subjects with type 1 diabetes. Diabetes Care 2007;30(12):3023-5


15) Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth


with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation


continuous glucose monitoring randomized trial. Diabetes Technol Ther 2010;12(7


):507-15


16) Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved


metabolic control in pediatric patients with type 1 diabetes: a controlled crossover


study. Pediatrics 2003;111(5 Pt 1):933-8


17) De Block C, Manuel-y-Keenoy B, Van Gaal L. A review of current evidence with


continuous glucose monitoring in patients with diabetes. J Diabetes Sci Technol


2008;2(4):718-27


18) Vazeou A. Continuous blood glucose monitoring in diabetes treatment.


Diabetes Res Clin Pract 2011;93 (Suppl.1):S125-30


19) Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. Diabetes


Res Clin Pract 2008;82 (Suppl.2):S118-21


20) Vaddiraju et al. Technologies for Continuous Glucose Monitoring: Current


Problems and Future Promises. J Diabetes Sci Technol 2010;4(6):1540-1562


[FTAB]

[TAB]

Photo:


http://photos.prnewswire.com/prnh/20121024/567690



[FTAB]

CONTACTO: Additional background information on 'Diabetes and continuousglucose monitoring' and 'C8 MediSensors and the Optical Glucose Monitor'are available from the European media contacts below.C8 MediSensors, Inc: Paul Zygielbaum, CEO, (+1) 408 622 2070; Fred Toney,CFO, (+1) 408 622 2050, Paul Connolly, VP Marketing & Sales, (+1) 408 7246453;European Media Contacts: UK: Aurora Healthcare Communications, Amy Noise /Rachel Terry, ((+44) 7720 592 689 / (+44) 7720 592 687, Germany: WaggenerEdstrom, Munich, Michaela Grandek, (+49) 89 628 1750, Spain: BerbesAssociados, Diana Zugasti / Sara Nieto,(+34) 91 563 23 00